Skip to main content
Premium Trial:

Request an Annual Quote

BioReference Laboratories' Q4 Revenues Climb 18 Percent

NEW YORK (GenomeWeb) – BioReference Laboratories announced today that its fourth quarter revenues increased 18 percent year over year with the number of patients served jumping 9 percent.

The Elmwood Park, NJ-based clinical lab firm reported revenues of $227.6 million for its fiscal fourth quarter ended Oct. 31, up from $192.2 million for the fourth quarter of 2013.

The number of patients served grew to 2,550 in the quarter from 2,350 in Q4 2013, while revenue per patient increased 10 percent year over year to $88.67 from $80.80.

BRL posted net income of $18.3 million, or $.66 per share, for the quarter, compared to $11.1 million, or $.40 per share, for Q4 2013.

For FY 2014, BRL reported total revenues of $832.3 million, up 16 percent from $715.4 million in FY 2013. Its net income for the year was $46.8 million, or $1.68 per share, compared to $45.8 million, or $1.65 per share, for FY 2013.

BRL finished its fiscal year with $17.5 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.